首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1783篇
  免费   105篇
  国内免费   5篇
耳鼻咽喉   25篇
儿科学   60篇
妇产科学   88篇
基础医学   178篇
口腔科学   51篇
临床医学   133篇
内科学   422篇
皮肤病学   11篇
神经病学   96篇
特种医学   64篇
外科学   343篇
综合类   26篇
预防医学   84篇
眼科学   14篇
药学   73篇
中国医学   6篇
肿瘤学   219篇
  2023年   19篇
  2022年   9篇
  2021年   43篇
  2020年   20篇
  2019年   39篇
  2018年   56篇
  2017年   51篇
  2016年   32篇
  2015年   35篇
  2014年   59篇
  2013年   78篇
  2012年   135篇
  2011年   132篇
  2010年   68篇
  2009年   62篇
  2008年   111篇
  2007年   145篇
  2006年   103篇
  2005年   98篇
  2004年   109篇
  2003年   126篇
  2002年   102篇
  2001年   28篇
  2000年   18篇
  1999年   16篇
  1998年   12篇
  1997年   17篇
  1996年   14篇
  1995年   14篇
  1994年   8篇
  1993年   5篇
  1992年   8篇
  1991年   6篇
  1990年   8篇
  1989年   11篇
  1988年   4篇
  1987年   5篇
  1986年   4篇
  1985年   3篇
  1984年   7篇
  1982年   5篇
  1981年   7篇
  1979年   6篇
  1978年   6篇
  1977年   3篇
  1976年   3篇
  1975年   4篇
  1971年   3篇
  1966年   3篇
  1964年   3篇
排序方式: 共有1893条查询结果,搜索用时 15 毫秒
1.
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible.  相似文献   
2.
PurposeManagement of head and neck cancers (HNC) in older adults is a common but challenging clinical scenario. We assess the impact of Stereotactic Body Radiation Therapy (SBRT) on survival utilizing the Geriatric-8 (G8) questionnaire.Materials and methods171 HNC patients, deemed medically unfit for definitive treatment, were treated with SBRT ± systemic therapy. G8 questionnaires were collected at baseline, at 4–6 weeks, and at 2–3 months post-treatment. Patients were stratified according to their baseline G8 score: <11 as ‘vulnerable’, 11–14 as ‘intermediate’, and >14 as ‘fit’. Overall survival (OS) was assessed through univariate Kaplan Meier analysis. Repeated measures ANOVA was used to determine if baseline characteristics affected G8 score changes.ResultsMedian follow-up was seventeen months. 60% of patients presented with recurrent HNC, 30% with untreated HNC primaries, and 10% with metastatic non-HNC primaries. Median age was 75 years. Median Charlson Comorbidity Index score was 2. 51% of patients were ‘vulnerable’, 37% were ‘intermediate’, and 12% were ‘fit' at baseline, with median survival of 13.2, 24.3, and 41.0 months, respectively (p = .004). Patients who saw a decrease in their follow-up G8 score (n = 69) had significantly lower survival than patients who had stable or increased follow-up G8 scores (n = 102), with median survival of 8.6 vs 36.0 months (p < .001).ConclusionThe G8 questionnaire may be a useful tool in upfront treatment decision-making to predict prognosis and prevent older patients from receiving inappropriate anti-cancer treatment. Decline in follow-up G8 scores may also predict worse survival and aid in goals of care following treatment.  相似文献   
3.
Cutaneous histiocytoses constitute a heterogeneous group of diseases characterised by the cutaneous accumulation of cells with the cytological and phenotypic features of macrophages or dendritic cells. The clinical spectrum ranges from self-resolving, skin-limited conditions to severe, multiorgan disease with a high morbidity rate. Until recently, cutaneous histiocytoses were classified according to the immunophenotype of the pathological cells, with differentiation between Langerhans cell histiocytosis (LCH) [CD1a+, CD207 (langerin)+] and non-Langerhans cell histiocytosis (CD68+, CD163+, CD1a?, CD207?). Over the last 12 years, a number of new pathophysiological findings (in particular, molecular pathology results) regarding histiocytoses have contributed to a new classification based on molecular alterations, as well as on clinical and imaging characteristics and the phenotype. The most frequent entities in children are juvenile xanthogranuloma and LCH.  相似文献   
4.
5.
6.
The spread of multidrug-resistant bacteria is an ever-growing concern, particularly among Gram-negative bacteria because of their intrinsic resistance and how quickly they acquire and spread new resistance mechanisms. Treating infections caused by Gram-negative bacteria is a challenge for medical practitioners and increases patient mortality and cost of care globally. This vulnerability, along with strategies to tackle antimicrobial resistance development, prompts the development of new antibiotic agents and exploration of alternative treatment options. This article summarises the new antibiotics that have recently been approved for Gram-negative bacterial infections, looks down the pipeline at promising agents currently in phase I, II, or III clinical trials, and introduces new alternative avenues that show potential in combating multidrug-resistant Gram-negative bacteria.  相似文献   
7.
8.
9.
10.
The purpose of this study was to evaluate the frictional resistance of various bracket/archwire combinations. The friction testing apparatus allowed dynamic and progressive bracket tipping and uprighting concurrent with linear bracket traction which experimentally approximated canine retraction with sliding mechanics. Multiple ANOVA using general linear models procedure demonstrated significant effects (P < 0.05) for bracket type, archwire type, archwire size, and archwire shape, as well as pair-wise interactions for bracket type/archwire type, bracket type/archwire size, bracket type/archwire shape, archwire type/archwire size, archwire type/archwire shape, and archwire size/archwire shape. Duncan’s multiple range test (P < 0.05) revealed the general trends regarding frictional performance of brackets and archwires tested, while Least squares means table (P < 0.05) illustrated significant interactions of pair-wise factors that differed from the general trends. It was concluded that: (1) Ceramic brackets with and without metal slots had the greatest friction followed by metal brackets, active self-ligating brackets, variable self-ligating brackets, and passive self-ligating brackets. (2) Stainless steel and braided stainless archwires measured greater friction than nickel-titanium. (3) Smaller dimension wires had less friction than larger wires, and round wires had less friction than rectangular wires. In addition, consideration of specific bracket-archwire coupling appear to reduce the frictional resistance with sliding.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号